Compare GSL & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | PGEN |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | Greece | United States |
| Employees | 7 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | GSL | PGEN |
|---|---|---|
| Price | $38.34 | $4.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $43.50 | $8.33 |
| AVG Volume (30 Days) | 232.1K | ★ 5.2M |
| Earning Date | 05-18-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.05 | $1.23 |
| 52 Week High | $41.40 | $5.47 |
| Indicator | GSL | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 56.73 |
| Support Level | $36.82 | $3.97 |
| Resistance Level | $38.52 | $4.43 |
| Average True Range (ATR) | 0.93 | 0.23 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 41.28 | 60.53 |
Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.